Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Harvard Business School
Queensland Health
Cerilliant
Dow
UBS
Accenture
McKinsey
Covington
Novartis

Generated: December 10, 2017

DrugPatentWatch Database Preview

Patents Expiring in February 2023

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Aralez PharmsYOSPRALAaspirin; omeprazoleTABLET, DELAYED RELEASE;ORAL205103-002Sep 14, 2016RXYesYes► Subscribe► Subscribe► SubscribeY
Horizon Pharma UsaVIMOVOesomeprazole magnesium; naproxenTABLET, DELAYED RELEASE;ORAL022511-002Apr 30, 2010ABRXYesNo► Subscribe► Subscribe► SubscribeYRELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
Horizon Pharma UsaVIMOVOesomeprazole magnesium; naproxenTABLET, DELAYED RELEASE;ORAL022511-001Apr 30, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeYRELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
Aralez PharmsYOSPRALAaspirin; omeprazoleTABLET, DELAYED RELEASE;ORAL205103-001Sep 14, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
Aralez PharmsYOSPRALAaspirin; omeprazoleTABLET, DELAYED RELEASE;ORAL205103-001Sep 14, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
Aralez PharmsYOSPRALAaspirin; omeprazoleTABLET, DELAYED RELEASE;ORAL205103-002Sep 14, 2016RXYesYes► Subscribe► Subscribe► SubscribeY
Shire Dev LlcVYVANSElisdexamfetamine dimesylateTABLET, CHEWABLE;ORAL208510-006Jan 28, 2017RXYesYes► Subscribe► Subscribe► SubscribeYFOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-001Feb 23, 2007RXYesNo► Subscribe► Subscribe► SubscribeYINDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-006Dec 10, 2007RXYesNo► Subscribe► Subscribe► SubscribeY
Shire Dev LlcVYVANSElisdexamfetamine dimesylateTABLET, CHEWABLE;ORAL208510-004Jan 28, 2017RXYesNo► Subscribe► Subscribe► SubscribeFOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Baxter
Daiichi Sankyo
Colorcon
McKesson
Cipla
Queensland Health
Johnson and Johnson
Moodys
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot